Table 6 Incidence of ADR in different drug-pair combinations
| COVID-19 drug pair | ADR |
|---|---|
| Atazanavir–hydroxychloroquine | 55 (25.3%) |
| Lopinavir/ritonavir–hydroxychloroquine | 34 (15.7%) |
| Lopinavir/ritonavir–interferon beta-1b | 5 (2.3%) |
| Atazanavir–favipiravir | 1 (0.5%) |
| Lopinavir/ritonavir–chloroquine | 1 (0.5%) |